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PURPOSE: This study aimed to assess the association between alendronate use and bone 
mineral density (BMD) change in subjects with moderate-severe chronic kidney disease 
(CKD). 
METHODS: We created a cohort of CKD stage 3B+ patients by linking all DXA-based 
measurements in the Funen area, Denmark, to biochemistry, national health registries, and filled 
prescriptions. Exposure was dispensation of alendronate and outcome was annualized % change 
in BMD at the femoral neck, total hip, and lumbar spine. Individuals were followed from first 
BMD to the latest of subsequent DXA measurements. alendronate non-users were identified 
using incidence density sampling and matched groups were created using propensity scores. 
Linear regression was used to estimate average differences in the annualized BMD. 
RESULTS: Use of alendronate was rare in this group of patients: propensity score matching 
(PSM) resulted in 71 alendronate users and 142 non-users with stage 3B+ CKD (as in the one 
year before DXA). Whilst alendronate users gained an average 1.07% femoral neck BMD per 
year, non-users lost an average 1.59% per annum. The PSM mean differences in annualized BMD 
were +2.65% (1.32%, 3.99%), +3.01% (1.74%, 4.28%), and +2.12% (0.98%, 3.25%) at the 
femoral neck, total hip, and spine BMD, respectively, all in favor of alendronate users. 
CONCLUSION: In a real-world cohort of individuals with stage 3B+ CKD, use of  alendronate 
appears associated with a significant improvement of 2-3% per year in the femoral neck, total 
hip, and spine BMD. More data are needed on the anti-fracture effectiveness and safety of 
bisphosphonate therapy in moderate-severe CKD. 
Keywords: bisphosphonates, bone mineral density, chronic kidney disease, osteoporosis, 
risk-set matching, propensity score 
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Mini Abstract 
Bisphosphonates are contraindicated in moderate to severe chronic kidney disease patients. 
However, they are used to prevent fragility fractures in patients with impaired kidney function, 
despite a lack of evidence on their effects on bone density in these patients. We demonstrated 
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Chronic kidney disease (CKD) is a multi-factorial disease associated with a range of metabolic 
diseases and complications. The prevalence of these complications increases rapidly in patients 
with stage 3B, an estimation of glomerular filtration rate (eGFR) below 45 ml/min/1.73m2 (1). 
It is also an independent risk factor for osteoporosis. More than one in four people with 
osteoporosis have moderate or severe CKD (2). CKD has been shown to predict not only low 
bone mass due to accelerated bone loss (3) but also fracture risk, with a doubled risk in patients 
with stage 3 CKD (eGFR between 30–59 ml/min/1.73m2) (4), a 2.5 to 3-fold risk in those with 
stage 3B CKD (4), and a four times higher fracture incidence amongst patients with stage 4 
CKD (eGFR between 15-29 ml/min/1.73m2) (5, 6) or in renal replacement therapy (7, 8). 
Osteoporosis may develop in patients with a reduced eGFR due age-related decrease in renal 
function or in patients with intrinsic renal disease (1). Patients with CKD due to intrinsic renal 
disease often have additional risk factors for osteoporosis such as glucocorticoid use, 
hyperparathyroidism, and vitamin D deficiency (9). Bone mass or bone mineral density (BMD) 
is a recognized key determinant of future fracture risk in postmenopausal women (10) and patients 
with CKD, next to bone microarchitecture, bone geometry, and rate of turnover (11). 
Measurement of BMD at the lumbar spine, femur neck, or total hip by dual energy X-ray 
absorptiometry (DEXA) is the standard method for diagnosis of osteoporosis and evaluating 
fracture risk, particularly in non-CKD patients. However, its significance and interpretation in 
CKD patients have been controversial due to a combination of CKD-induced changes in bone 
and mineral metabolism (1). Recently, several studies have shown that BMD is a good predictor 
of fracture risk in CKD stages 3-5 as a result the 2017 Kidney Disease Improving Global 
Outcomes (KDIGO) guideline recommended systematic BMD measurement in CKD patients 
(12-14). BMD measurement is often assessed before anti-fracture treatment decisions are made, 
this is in part due to the fact that therapeutic trials in osteoporosis usually require a low BMD 
value as an entry criterion. Hence, medications are often licensed for use in patients below a 
given BMD threshold. In addition, BMD is also monitored as a surrogate marker to evaluate 
the response of an individual patient to treatment as well as the efficacy of a treatment in clinical 
trials (15-18). 
The most important clinical goal of osteoporosis treatment is the reduction in fracture risk, due 
to high morbidity and mortality associated with it, especially in elderly people. While there are 
effective therapies to reduce the risk of osteoporotic fracture, the use of oral bisphosphonates 
(i.e., first line anti-osteoporosis therapies) is restricted in patients with CKD for several reasons. 
First, there are safety concerns related to the risk of bisphosphonates worsening kidney function 
and other adverse events which are already increased in patients with CKD such as severe 
hypocalcemia or hyperphosphatemia, or acute kidney injury (9). Second, given the biological 
mechanism of how CKD weakens bone differs from osteoporosis, it is far from established that 
bisphosphonates will have a similar beneficial effect in improving BMD. Importantly, 
participants in these trials with CKD are likely to be healthier and have fewer comorbidities 
compared with patients with CKD in the real world setting. This leaves moderate-severe CKD 
patients with a very high fracture risk effectively untreatable. In addition, the relationship 
between changes in BMD during treatment with oral bisphosphonates and fracture risk is still 
less clear since the numbers of patients with moderate or severe CKD recruited for the pivotal 
 
4  
trials were low (15-17, 19-21). However, clinical trial participants with higher BMD gains on 
oral bisphosphonate therapy had a significantly lower risk of fracture than participants with no 
change or a reduction in BMD (20). Hence, BMD is an accepted surrogate marker in bridging 
studies of anti-osteoporosis treatments (22) to test different dosing regimens (23), and efficacy 
in other populations such as men (24) and in patients taking glucocorticoids (25). 
The relationship between BMD change and fracture risk in postmenopausal osteoporosis versus 
bone fragility in CKD may differ given the different aetiopathology of bone fragility in CKD (26) 
with particular reference to potential adynamic bone disease. The aim of this study was to examine 
the association between bisphosphonate use and changes in BMD over time in subjects with 




We used the Odense University Hospital Database (OUHD) which holds DXA-measured BMD 
data for the whole of the Funen region, the second-largest island of Denmark, comprising 
36,024 individuals examined between August 1990 and February 2015. Serum creatinine is part 
of the routine panel of blood tests performed at the Odense University Hospital as part of 
osteoporosis care. Primary care practices and hospitals in this Danish region use the same 
clinical biochemistry laboratory, making all biochemistry values (including serum creatinine 
tests) available for this study. We were able to calculate the eGFR for participants in this cohort 
using the CKD-EPI formula (27). Pharmacy drug dispensations of primary and secondary care 
prescriptions can be tracked back to 1995 from the Danish Prescriptions Register and linked using 
unique national patient identifiers to OUHD. Pharmacy dispensations are recorded using 
Anatomic Therapeutic Classification (ATC) codes. 
The Open Patient Data Exploratory Network (OPEN) provides a unique platform for linking 
clinical, dispensation, and biochemistry data. It is an approved Statistics Denmark institutional 
partner for linking to diagnoses and comorbidity recorded using ICD-10 codes in Danish 
hospital records. The Network has previously been used to link clinical biochemistry to fracture 
outcomes in numerous studies (28-32). Ad-hoc extraction and linking to renal function from 
the Odense University Hospital clinical biochemistry database was done as part of this study 
using similar approach. In the OUHD, 30% of individuals examined (over 10,000 subjects) were 
recommended osteoporosis treatment, with alendronate as the first line drug. In Denmark, 
reimbursement for alendronate and other alendronates require a DXA assessment or an X-ray 
verified spine or hip fracture. The study was approved by the Data Protection Agency (OUH 
15/37999) and by Statistics Denmark (ref.705079). All statistical analyses were done on de-
identified patient data merged at Statistics Denmark. 
Study participants and Design 
All patients registered in OUHD aged 40 years or older at the age of biochemistry testing, with at 
least one eGFR measurement below 45 ml/min/1.73 m2 (CKD stages 3B, 4, and 5), at least two 
years of follow-up data available, and with at least two DXA BMD measurements recorded 2 or 
more years apart were eligible for inclusion. Previous users of any anti-osteoporosis medication 
(except calcium and vitamin D supplements) in the year before eGFR testing and those with 
more than 1 year between the closest renal measurement (eGFR) and DXA (BMD 
measurement) were excluded. The first dispensation of a alendronate (therapy initiation) was 
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considered the index date for alendronates users. Participants, users of alendronate, were risk-set-
matched with replacement to non-users on +/-5 years of the year of birth at index date, meaning 
a non-user could be matched to several alendronate users. For every alendronate user, up to five 
non-users at index date were randomly selected from a large pool of non-users. Selection bias 
was thus minimized while preserving statistical power, as initial non-users could become 
alendronate users and will be included later as users. 
Exposure, outcome and confounders 
Alendronate use, defined by pharmacy dispensations in the Danish Prescriptions Register, was 
the main exposure. Users of alendronates were identified using pre-specified lists of ATC codes. 
Like prescriptions, dispensation data do not necessarily reflect treatment duration. Treatment 
episodes were created using a previously validated algorithm that accounts for non-adherence 
(or non-compliance) and defines treatment episodes of continuous exposure. Any overlapping 
prescriptions of the same drug were interpreted as early collection of a repeat prescription. Any 
overlapping days between two prescriptions of the same drug were added to the end of the period 
covered by the two prescriptions. Any two prescriptions of the same drug were concatenated and 
considered as one prescription if the gap between the end of the first prescription and the start 
of the second prescription was less than 30 days. 
 
The primary study outcome was annualized femoral neck BMD percentage change, relative to 
the previous or baseline BMD, up to 3 years after alendronate use (or non-use), measured using 
a DXA. If more than two measurements were available, the last DXA measurement 2-3 years 
from the index date was considered. Any measurements within 1 year between each other were 
excluded, as they were unlikely to provide clinically relevant information. Secondary outcomes 
were similarly defined as annualized BMD percentage changes, measured at the lumbar spine 
and total hip. If participants had serial spine measurements, we used the vertebrae that were still 
assessable at the last recorded visit to calculate the rate of BMD change. A sensitivity analysis 
used DXA measurements taken 3-5.5 years after the index date, since change in BMD has been 
shown to plateau after 3 years (33). 
Potential confounders were pre-identified using clinical knowledge and a literature review. 
Confounders were measured at baseline and included age, sex, BMI, baseline eGFR, fracture 
history, co-morbidities (Charlson index, renal disease, and diabetes), hospital contacts in the 
previous year, and concomitant drug use (number of ATC in the year before index, aromatase 
inhibitors, antihypertensives, antidepressants, and antidiabetics). As systemic steroids have an 
effect on BMD and are commonly used in certain renal conditions, we accounted for these drugs 
in a more granular fashion. We calculated the number of defined daily doses in the previous year 
and stratified into quartiles. 
Statistical analyses 
In a primary analysis, propensity scores for alendronate use were estimated using multivariable 
logistic regression, including the confounders (Table 1). Interactions between age and BMI as 
well as age and baseline eGFR were added to the propensity score equation to improve the 
balance of the baseline characteristics. The calculated propensity scores were used to match 
each alendronate user with to up to five comparable non-users with a caliper width of at most 
0.02 SDs on the logit of the propensity scores. Balance before and after matching was checked 
using the absolute standardized mean difference (ASMD). An ASMD of 0.10 or less was 
considered acceptable and representative of a good balance. 
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Linear regression modelling was used to estimate average differences (expressed as beta 
coefficient and 95% confidence intervals) in the annualized BMD change (per cent versus index 
measure) at the femoral neck (primary outcome), total hip, and lumbar spine (secondary 
outcomes). Two post-hoc analyses were conducted to deal with the low number of alendronate 
users eligible for inclusion in the final analyses: 
i) A linear regression model including all eligible alendronate users and non-users and adjusted 
for the previously calculated propensity scores. ii) A multivariable linear regression model, 
adjusting for the same set of confounders included in the propensity score model, was fitted to 
model annualized percentage BMD change according to alendronate use, with 95% confidence 
intervals. 
All analyses were conducted using R (34) and STATA 15 (35). Statistical syntax was 
programmed at Oxford using mock data extracted from the analytical dataset. These programs 
were run ‘in situ’ by a statistician at Odense, Denmark. Final results were verified by two of 
the authors (MSA and DPA). 
 
RESULTS 
Participants and baseline characteristics 
We identified 36,024 patients in the linked OUHD BMD database who were eligible for the 
study, including 12,544 (34.8%) patients who were alendronate users within the study period. 
We excluded 233 (1.9%) who were younger than 40 years at the time of therapy initiation, 
1,323/12,544 (10.5%) who did not have an eGFR measurement recorded in the previous year, 
and 10,586/12,544 (84.4%) who had an eGFR value of 45 or above. Of the remaining 402 
eligible alendronate users, a third (132/402, 32.8%) had no DXA measurement in the year 
before therapy initiation. Therefore, 270 alendronate users (264, 98% on alendronate) were 
eligible for the study (Figure 1). Among these, 35 (13.0%) died during follow-up, 93 (34.4%) 
discontinued alendronate therapy before having a repeat BMD, and 142 (52.6%) did not have a 
repeat BMD between 1 and 3.5 years after the first scan after therapy started. We, therefore, 
included 71 alendronate users in the study. In parallel, 23,713 non-users were initially available 
for comparison. Among these, 1,228 (5.2%) died during follow-up. Only 1,609 (6.8%) had 
repeat BMD measures between 1 and 3.5 years after their index DXA and were eligible for the 
analysis. 
 
INSERT FIGURE 1 
Baseline characteristics for all 270 eligible alendronate users and the final sample of 71 are 
reported in Table 1. As expected, participants included in the final analyses were younger (79 
verses 82 years old on average), healthier (54.9% versus 52.6% with a Charlson score of 0), 
and more likely to use systemic corticosteroids (40.8% versus 36.3%), statins (42.3% versus 
39.3%), and antihypertensives (81.7% versus 73.3%) than those excluded. 
 
INSERT TABLE 1 HERE 
 
Table 2 reports baseline characteristics for the included participants, stratified by alendronate 
use. Both groups only included women and had an average age of 79-80 years. As expected, 
alendronate users had a much lower index BMD (0.56 versus 0.62 g/cm2 at femoral neck), were 
more likely to use systemic corticosteroids (40.8% versus 32.8), and had a much higher 
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prevalence of previous fracture (7.0% versus 1.7% for hip fracture history) than non-users. Low 
bone mass, prevention of glucocorticoid-induced osteoporosis, and secondary fracture 
prevention are the most likely indicators of alendronates in patients with moderate-to-severe 
CKD. All of these variables and the confounders listed in Table 1 were adjusted for using 
propensity score and multivariable regression models. 
INSERT TABLE 2 HERE 
 
Propensity score matching 
Before matching, the two groups had little overlap in their propensity scores, with median 
(interquartile range) of 0.49 (0.17, 0.84) for the alendronate users and below 0.001 (<0.001, 
0.003) for the non-users. After matching, the median (IQR) of the propensity scores were more 
similar, at 0.19 (0.08, 0.43) in the alendronate users and 0.13 (0.04, 0.43) in non-users. 
Forty of the 71 alendronate users were matched to 142 non-users. Matching improved balance 
and reduced differences to acceptable limits (ASMD < 0.1) for most of the assessed participant 
characteristics included in the model (Figure 3). However, relevant differences remained for 
key confounders, including baseline (index) femoral neck BMD (0.55 versus 0.62 gr/cm2), use 
of systemic glucocorticoids (27.5% versus 35.9%), and previous hip fracture history (12.5% 
versus ¡ 3.5%). Charlson comorbidity index, polypharmacy, number of hospital visits, history 
of key comorbid conditions (complicated diabetes, hypertension, chronic heart failure, and 
COPD), and previous use of antiepileptics or antidiabetic therapies also still had unacceptable 
imbalances (ASMD > 0.1) after matching. Matching excluded more than 91% of the potentially 
eligible alendronate non-users. 
INSERT FIGURE 2 
 
Annualized bone mineral density changes over time 
In the propensity-matched cohorts (pre-specified primary analysis), alendronate non-users lost 
on average 1.59% of their baseline femoral neck BMD per year, whereas alendronate users 
increased their BMD by 1.07% per year of therapy. The average percentage BMD changes in the 
propensity-score-matched cohort are detailed in Table 3. In a linear regression model, after 
propensity score matching, the mean difference (95% CI) in percentage annual change in femoral 
neck BMD between alendronate users and non-users favored the users by +2.65% (1.32%, 
3.99%) per year of alendronate exposure. Average femoral neck BMD change per month for 
alendronate non-users and users was shown in Figure 3a. 
 
INSERT FIGURE 3 
In the analyses including the full cohort, alendronate non-users lost on average 1.67% of their 
baseline femoral neck BMD per year, whereas alendronate users gained an average 0.63% per 
year on treatment. The results of linear regression modelling supported the findings from the 
propensity-matched analysis, with a multivariable-adjusted beta coefficient (mean difference 
between groups) of +2.14% (1.22%, 3.05%) and a propensity-score-adjusted beta of +2.15% 
(0.97%, 3.34%) per year. 
 
INSERT TABLE 3 HERE 
 
In the analysis of secondary outcomes, BMD at the spine increased among alendronate users by 
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3.98% per year for the full cohort and by 3.36% in the propensity-matched cohort. Alendronate 
non-users in the full cohort increased their BMD by 0.65% per year and in the matched cohort 
by 0.34% per year. The mean (95% CI) difference in percentage BMD change was again in 
favor of alendronate users, with betas of +3.01% (1.74%, 4.28%) per year for the propensity-
score-matched analysis, +2.14% (1.22%, 3.05%) for the multivariable analysis, and +2.87% 
(1.62%, 4.12%) for the propensity-score-adjusted analysis. Average spine BMD change per 
month for alendronate non-users and users was shown in Figure 3b. 
 
Total hip BMD improved by an average of 0.82% per year for the full cohort of alendronate users 
and by 0.95% for the matched cohort. Alendronate non-users in the full cohort lost on average -
2.14% BMD per year and those in the propensity-matched cohort lost -1.16% per year. The mean 
difference was +2.12 (0.98%, 3.25%) per year in favor of alendronate users in the propensity-
score-matched model, +2.29% (1.46%, 3.11%) for the multivariable model, and +1.91% 
(0.82%, 3.00%) for the propensity-adjusted model. Average hip bone mineral density (BMD) 
change per month for alendronate non-users and users was shown in Figure 3c. 
 
The pre-specified sensitivity analysis using DXA measures taken between 3 and 5.5 years after 
index date could not be performed in the matched analysis as only 1 alendronate user and 12 non-
users had valid follow-up data in this time window. 
 
DISCUSSION 
We used region-wide population-based data from Funen, Denmark. Despite the size of the 
source dataset, only 71 female participants were identified with stages 3B-5 CKD who were 
given alendronates, continued the treatment for at least 1 year, and had at least two recorded 
BMD measurements. From around 200 eligible participants not using alendronates, only 1,609 
records of BMD measurements at different times were available. Propensity score matching led 
to the exclusion of almost half of the users and more than 90% of the non-users. Although 
matching helped to reduce confounding, imbalance remained when alendronate users and 
matched non-users were compared, including in key confounders such as baseline BMD, fracture 
history, and use of systemic steroids. The small sample might demonstrate the low likelihood of 
Danish patients with stages 3B-5 CKD being prescribed alendronates, reflecting the safety 
concerns and lack of evidence on efficacy that led to this study. 
The primary propensity-matched cohort analysis identified a significant, clinically relevant 
effect, with a +1.1% femoral neck BMD gain per year in alendronate users, compared to a -
1.6% bone loss at the same site per year in matched non-users. This is equivalent to a +2.7% 
difference in BMD change per year in favor of alendronate users. The full cohort multivariable 
and propensity-adjustment analyses found consistent results, with a +2.1% and +2.65% 
difference per year favoring alendronate use, respectively. Consistent results were found for the 
secondary outcomes. Lumbar spine and total hip BMD improved by 3.4% and 1.0% per year in 
alendronate users, compared to 0.3% and -1.2% (bone loss) per year in the propensity score 
matched non-users, respectively. This equated to a significant +3.0% per year average 
difference in the lumbar spine and a +2.1% difference in the total hip, both favoring alendronate 
users. Multivariable and propensity-adjusted models found similar results. 
Limitations and strengths 
 
This cohort analysis has limitations. The eligibility criteria excluded most of the records in the 
database including male patients and users of other oral bisphosphonates. Although this was 
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not surprising, as bisphosphonates are to be used with caution in patients with stage 3 CKD and 
are contraindicated in stages 4-5, it is possible that the generalizability of the findings might 
have been compromised. The need for repeat DXA testing to obtain BMD change over time, 
outcome of interest in this study, excluded more than half of the potentially eligible 
bisphosphonate users. These patients may have differed from the included participants, as BMD 
monitoring during treatment is not routine practice in actual care conditions. Current evidence 
suggests that routine monitoring of BMD within 3 years of starting bisphosphonates in 
postmenopausal women is clinically unhelpful1 (36) and may contribute to a lack of follow-up 
densitometry in an unexpectedly large proportion of those treated. Trials of bisphosphonates 
have shown a significant attenuation of BMD gain after the first 12 months of therapy (15, 37). 
The overlap between alendronate users and non-users was small, excluding almost half of the 
alendronate users and over 90% of the non-users when propensity score matching was applied. 
However, the multivariable and propensity-adjustment models that include the full cohort gave 
reassuringly similar estimates to the propensity-matched analysis. Only women were included 
in these analyses, possibly related to the high rate of exclusion. The findings are thus limited to 
the female population. 
This analysis also has some strengths. The dataset used has high granularity and quality, and 
comprises information from a number of linked data sources. It is a unique data source for 
research as it includes comorbidity, hospital contacts, biochemistry, drug use, BMD testing, and 
related questionnaires (38). The dataset also includes most of the population of a whole region 
of Denmark, thus maximizing the external validity of our findings. 
The observed differences in femoral neck BMD in alendronate user versus nonuser participants 
over 1 year were similar to those observed in trials of postmenopausal women (15). However, our 
alendronate users had only half the increase in BMD seen in the trial’s treatment arm after 1 
year of therapy, where the increase in femoral neck BMD was 2% with alendronate (15). 
Although not statistically significant, the total hip is certainly the most relevant site of the upper 
extremity of the femur in the context of a follow-up with or without treatment. It is difficult to 
make generalization given the small size of our study in the findings. The difference at the spine 
in our alendronate users was also smaller than seen in the trial, where there was a 4.2% increase 
after 1 year. It is difficult to compare our unexposed CKD participants with those in the placebo 
arm of the trial as the trial participants who received the placebo also received calcium and 
vitamin D supplements. 
 
Early BMD changes during therapy are difficult to interpret due to regression to the mean (39) 
with most patients who lose BMD in the first year of alendronate therapy going on to have 
significant increases in BMD in the second year. Our attempt to address this issue in a sensitivity 
analysis was inhibited due to lack of power. The relationship between BMD change and fracture 
risk may differ in postmenopausal osteoporosis and bone fragility in CKD as they have different 
aetiopathology, with the potential involvement of adynamic bone disease in bone fragility in 
CKD (26). The disconnect between treatment-related BMD increases and fracture risk is 
exemplified in trials of fluoride therapy, where increased BMD was associated with a paradoxical 
increased risk of fracture (40). The artefactual effects of vascular calcification on spinal BMD 





We demonstrated that alendronate therapy had a positive effect on BMD in patients with stages 3B+ 
CKD. BMD is the best surrogate available for bone strength in clinical practice, and RCTs using 
BMD as a primary outcome have been accepted by regulators as bridge studies to extend the 
indication of alendronate therapies for men (25) and for the prevention or treatment of steroid-
induced osteoporosis (38).We found that BMD improved more (by 2% to 3% per year, 
depending on skeletal site) in alendronate users than non-users. In fact, BMD decreased over 
time when participants were off alendronate therapy, by about 1% per year in the femoral neck 
and total hip. The result was an average difference of +2.7%, +3%, and +2.1% BMD change 
per year in the femoral neck, lumbar spine, and total hip, respectively, all in favor of alendronate 
users. These findings were not modified by age, sex (the analysis only included women), 
previous fracture history, or baseline renal function. 
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